Bioventus Inc
NASDAQ:BVS
US |
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
|
US |
Estee Lauder Companies Inc
NYSE:EL
|
Consumer products
|
|
US |
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
|
US |
Church & Dwight Co Inc
NYSE:CHD
|
Consumer products
|
|
US |
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
|
US |
American Express Co
NYSE:AXP
|
Financial Services
|
|
US |
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
|
US |
Visa Inc
NYSE:V
|
Technology
|
|
CN |
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
|
US |
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
|
US |
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
|
US |
Coca-Cola Co
NYSE:KO
|
Beverages
|
|
US |
Target Corp
NYSE:TGT
|
Retail
|
|
US |
Walt Disney Co
NYSE:DIS
|
Media
|
|
US |
Mueller Industries Inc
NYSE:MLI
|
Machinery
|
|
US |
PayPal Holdings Inc
NASDAQ:PYPL
|
Technology
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
3.76
13.71
|
Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
Johnson & Johnson
NYSE:JNJ
|
US | |
Estee Lauder Companies Inc
NYSE:EL
|
US | |
Exxon Mobil Corp
NYSE:XOM
|
US | |
Church & Dwight Co Inc
NYSE:CHD
|
US | |
Pfizer Inc
NYSE:PFE
|
US | |
American Express Co
NYSE:AXP
|
US | |
Nike Inc
NYSE:NKE
|
US | |
Visa Inc
NYSE:V
|
US | |
Alibaba Group Holding Ltd
NYSE:BABA
|
CN | |
3M Co
NYSE:MMM
|
US | |
JPMorgan Chase & Co
NYSE:JPM
|
US | |
Coca-Cola Co
NYSE:KO
|
US | |
Target Corp
NYSE:TGT
|
US | |
Walt Disney Co
NYSE:DIS
|
US | |
Mueller Industries Inc
NYSE:MLI
|
US | |
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
This alert will be permanently deleted.
Intrinsic Value
The intrinsic value of one BVS stock under the Base Case scenario is 10.12 USD. Compared to the current market price of 11.22 USD, Bioventus Inc is Overvalued by 10%.
The Intrinsic Value is calculated as the average of DCF and Relative values:
Valuation Backtest
Bioventus Inc
Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.
Start backtest now and learn if your stock is truly undervalued or overvalued!
Stock is trading at its lowest valuation over the past 5 years.
To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.
The backtest for BVS cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.
Fundamental Analysis
Select up to 3 indicators:
Select up to 3 indicators:
Months
Months
Months
Months
Select up to 2 periods:
Revenue & Expenses Breakdown
Bioventus Inc
Balance Sheet Decomposition
Bioventus Inc
Current Assets | 308.9m |
Cash & Short-Term Investments | 32m |
Receivables | 137.3m |
Other Current Assets | 139.6m |
Non-Current Assets | 483.3m |
Long-Term Investments | 2.1m |
PP&E | 42.3m |
Intangibles | 432m |
Other Non-Current Assets | 6.9m |
Current Liabilities | 231.5m |
Accounts Payable | 24.4m |
Accrued Liabilities | 138.1m |
Other Current Liabilities | 68.9m |
Non-Current Liabilities | 409.8m |
Long-Term Debt | 344.7m |
Other Non-Current Liabilities | 65.1m |
Earnings Waterfall
Bioventus Inc
Revenue
|
536.9m
USD
|
Cost of Revenue
|
-179.7m
USD
|
Gross Profit
|
357.2m
USD
|
Operating Expenses
|
-343.3m
USD
|
Operating Income
|
13.9m
USD
|
Other Expenses
|
-55.9m
USD
|
Net Income
|
-42m
USD
|
Free Cash Flow Analysis
Bioventus Inc
USD | |
Free Cash Flow | USD |
BVS Profitability Score
Profitability Due Diligence
Bioventus Inc's profitability score is 36/100. The higher the profitability score, the more profitable the company is.
Score
Bioventus Inc's profitability score is 36/100. The higher the profitability score, the more profitable the company is.
BVS Solvency Score
Solvency Due Diligence
Bioventus Inc's solvency score is 36/100. The higher the solvency score, the more solvent the company is.
Score
Bioventus Inc's solvency score is 36/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
BVS Price Targets Summary
Bioventus Inc
According to Wall Street analysts, the average 1-year price target for BVS is 14.79 USD with a low forecast of 12.12 USD and a high forecast of 17.85 USD.
Dividends
Current shareholder yield for BVS is .
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
Ownership
BVS Insider Trading
Buy and sell transactions by insiders
Period | Sold | Bought | Net |
---|---|---|---|
3 Months |
|
|
|
6 Months |
|
|
|
9 Months |
|
|
|
12 Months |
|
|
|
Profile
Country
Industry
Market Cap
Dividend Yield
Description
Bioventus, Inc. global medical technology company which focuses on developing and commercializing and proprietary orthobiologic products for the treatment of patients suffering from an array of musculoskeletal conditions. The company is headquartered in Durham, North Carolina and currently employs 1,200 full-time employees. The company went IPO on 2021-02-11. The firm is focused on developing and commercializing clinically and minimally invasive treatments that engage and enhance the body’s natural healing process. The Company’s portfolio of products includes OA joint pain treatment and joint preservation, bone graft substitutes and minimally invasive fracture treatment. The OA joint pain treatment and joint preservation is focused on orthopedics. Its bone graft substitutes (BGSs) offers portfolio of products including human tissue allografts and synthetics. Its BGS products can be used in conjunction with any orthopedic fixation and spinal fusion implant. They are designed to improve bone fusion rates following spinal fusion and other orthopedic surgeries and reduce the need for using the patient’s own bone.
Contact
IPO
Employees
Officers
The intrinsic value of one BVS stock under the Base Case scenario is 10.12 USD.
Compared to the current market price of 11.22 USD, Bioventus Inc is Overvalued by 10%.